Posted by Michael Wonder on 14 Mar 2024
FDA approves first treatment for patients with liver scarring due to fatty liver disease
14 March 2024 - Today, the US FDA approved Rezdiffra (resmetirom) for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise.
The safety and efficacy of Rezdiffra was evaluated based on an analysis of a surrogate endpoint at month 12 in a 54 month, randomized, double-blind placebo-controlled trial.
